Patients with non-small cell lung cancer benefit from targeted therapy, and the New England Journal of Medicine publishes the clinical results of Lu Shun and others
On June 3, the latest clinical research results of Professor Lu Shun from the Oncology Department of Shanghai Chest Hospital, as a world-leading researcher, were published in the top international journal "New England Journal of Medicine", leading the world in the treatment of stage III unresectable non-small cell lung cancer. A new trend in treatment. Professor Lu Shun is the first author and corresponding author of this article.
Stage III non-small cell lung cancer accounts for about one-third of the total number of lung cancers, and the total number of patients is huge. Among them, patients with unresectable stage III non-small cell lung cancer and those with EGFR gene mutations have not achieved satisfactory results under the previous treatment strategy of "radiotherapy, chemotherapy and immune consolidation", and there is a huge demand for treatment.
Based on this, in 2019, the world's first randomized controlled, double-blind, multi-center international study of "targeted therapy after radical chemoradiotherapy" for patients with stage III non-small cell lung cancer with EGFR-sensitive mutations came into being. The study enrolled a total of 216 patients worldwide and randomly assigned them to the osimertinib group or the placebo group in a 2:1 ratio, with progression-free survival as the primary endpoint.
This is the first analysis of the LAURA study released in the New England Journal of Medicine. The study shows that in the osimertinib group compared with the placebo group, the progression-free survival of patients was 39.1 months and 5.6 months respectively, suggesting that in the After radical chemoradiotherapy, osimertinib can significantly improve the survival of patients with EGFR mutated stage III unresectable non-small cell lung cancer, and significantly reduce the risk of disease progression or death by 84%. At the same time, compared with the placebo group, the objective response rate and median response rate of patients in the osimertinib group were also significantly improved, and new metastases were significantly reduced.
At the 2024 American Society of Clinical Oncology Annual Meeting, LAURA's research results also made a "plenary report" speech, which received heated discussion and praise from experts in the global oncology field. The publication of this research results marks the success of the targeted treatment model for patients with stage III unresectable non-small cell lung cancer, and may rewrite the future treatment landscape. In the next step, the LAURA study will further explore aspects such as prolonging the overall survival of patients and the therapeutic effect of metastatic lesions.